JPRN-jRCT2080224996已完成1 期
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
研究概览
简要总结
A single dose of TAK-925 112 mg administered as a slow infusion over 9 hours in subjects with IH was well tolerated by most subjects with no major safety concerns. - Following a single 9-hour IV infusion of 112 mg TAK-925, mean observed systemic exposures were generally comparable to historical data.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1.A diagnosis of IH, as defined by the International Classification of Sleep Disorders-3 (ICSD-3) as verified by a previous nocturnal polysomnography (nPSG) and multiple sleep latency test (MSLT) study performed within the last 10 years.
- •2.Onset of hypersomnia between 10 and 30 years of age.
- •3.Seven consecutive days of actigraphy supported by a sleep diary obtained prior to the nPSG (Study Day -2) shows an average nightly sleep duration of greater than or equal to (>=) 420 minutes during the participant's normal nocturnal sleep period.
- •4.nPSG (Study Day-2) demonstrates that participant does not have other comorbid sleep disorders or clinically significant nocturnal hypoxemia (oxygen saturation less than or equal to (<=)80% for >=5% of total sleep time) and that their Apnea-Hypopnea Index (AHI) is less than or equal to (<=) 10 per hour, their periodic limb movement arousal index (PLMAI) <=15/hour, and that their total sleep time is >=6.5 hours.
- •5.Participants taking medication for treatment of excessive daytime sleepiness (EDS) must be willing to discontinue medication prior to randomization into the study.
- •6.Body mass index (BMI) of 18 through 33 kg/m^2 inclusive.
- •7.Epworth Sleepiness Scale (ESS) score >=11 at screening and on Day -2.
- •8.Blood pressure (BP) must be <140 mmHg (systolic) and <90 mmHg (diastolic) at screening and Study Day -2.
排除标准
- •1 .Average nightly sleep duration is <=8 hours (480 minutes) and has Insufficient sleep syndrome as evidenced by sleeping >2 hours/night more on off-days relative to work days as determined by actigraphy and sleep diary obtained prior to the nPSG (Study Day -2).
- •2. Positive urine screen for drugs of abuse and/or positive alcohol test at screening and Study Day -2.
- •3. Resting heart rate (HR) outside of the range of 40 to 90 beats per minute (bpm) off stimulants.
- •4. Screening electrocardiogram (ECG) reveals a QT interval with Fridericia correction method >450 ms (men) or >470 ms (women).
- •5. Usual bedtime later than 24:00 (midnight) or an occupation requiring nighttime shift work or variable shift work within the past 6 months, or travel with significant jet lag within 14 days before Study Day -2.
- •6. History of a sleep disorder other than IH, based on interviews at the screening visit, such as obstructive sleep apnea (OSA), restless legs syndrome, or periodic limb movements of sleep (PLMS) associated with arousals.
- •7. Use of any over-the-counter (OTC) or prescription medications with stimulating properties within 7 days prior to dosing or 5 half-lives (whichever is longer) that could affect the evaluation of EDS or use of sodium oxybate within 3 months of screening.
- •8. Nicotine dependence that is likely to have an effect on sleep (e.g., a participant who routinely awakens at night to smoke) and/or an unwillingness to discontinue all smoking and nicotine use during the confinement portion of the study (Day -2 to Day 4)..
- •9. Caffeine consumption of more than 600 mg/day for 7 days before Study Day 1 (1 serving of coffee is approximately equivalent to 120 mg of caffeine) and/or unwilling to discontinue all caffeine during the confinement portion of the study (Day -2 to Day 4).
- •10. Alcohol use that is likely to have an effect on sleep and/or an unwillingness to discontinue all alcohol use from 72 hours before check-in through discharge on Study Day 4.
- •11. History of epilepsy or seizures, including having had a single seizure or a history of childhood febrile seizures or has a clinically significant history of head trauma.
- •12. Answered YES on Questions 4 or 5 on the Suicidal Ideation subscale of the Columbia Suicide Severity Rating Scale (C-SSRS) at screening (defined period as 3 months prior to screening) or evidence of suicidal behavior within 6 months of screening as measured by the Suicidal Behavior subscale of the C-SSRS.
- •13. Diagnosis of major depressive disorder (DSM-5), within the past 6 months or Beck Depression Inventory II (BDI-II) total score of >16 at the screening visit.
- •14. History of cerebral ischemia, transient ischemic attack, intracranial aneurysm, or arteriovenous malformation.
- •15. Known coronary artery disease, a history of myocardial infarction, angina, cardiac rhythm abnormality, or heart failure.
研究者
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy AdultsHealthy VolunteersNCT03522506Takeda20
已完成
1 期
A Study of TAK-919 in Healthy Japanese Adults (COVID-19)Coronavirus Disease (COVID-19)JPRN-jRCT2071200069Kuriyama Kenji200
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy ParticipantsHealthy ParticipantsNCT03933488Takeda121
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935Healthy VolunteersNCT02201056Takeda48
已完成
1 期
Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With NarcolepsyHealthy Participants and Patients With NarcolepsyNCT03332784Takeda58